Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia Leukemia (2013) 27, 1411-1413; doi:10.1038/leu.2012.324
The t(9;22)(q34;q11) translocation, known as the Philadelphia chromosome (Ph), is present in B15-30% of adult patients with acute lymphoblastic leuremia (ALL). 1 This translocation results in the formation of breakpoint cluster region-Abelson (BCR-ABL) fusion gene and subsequent expression of the constitutively active 190-kDa BCR-ABL protein tyrosine kinase, which is distinct from the 210 kDa form of BCR-ABL observed in chronic myeloid leukemia (CML). 1 Before the development of BCR-ABL tyrosine kinase inhibitors (TKIs), chemotherapy and allogeneic stem cell transplantation (alloSCT) were the standard treatments for patients with Ph þ ALL. Relapse rates were high and long-term survival rates were low with these approaches. Imatinib combined with chemotherapy is now considered frontline treatment for Ph þ ALL. 1 For patients with Ph þ ALL who relapse following initial therapy, treatment with a second-generation BCR-ABL TKI may be an effective option. 2 Nilotinib was designed to inhibit BCR-ABL activity more potently and with greater specificity than imatinib. 3 In addition to being more potent than imatinib against the wild-type 190-and 210 kDa BCR-ABL proteins, nilotinib has activity against all known imatinib-resistant BCR-ABL mutants except T315I. 4 In a phase I study of nilotinib in patients with imatinib-resistant Ph þ CML or ALL, 2 of 13 (15.4%) patients with Ph þ ALL responded to nilotinib. 5 Here, we present the safety and efficacy of nilotinib in patients with refractory ALL treated on a Phase II study when all patients had either at least 24 months of treatment or were off study.
Patients aged X18 years with Ph þ ALL were eligible if they had relapsed or were refractory to the standard therapy, had adequate performance status, and normal cardiac, renal, and hepatic function. Patients with minimal residual disease (MRD) were eligible only if there was an indication of evolving relapse on the basis of increasing BCR-ABL transcript levels. 6 The study was conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent according to the institutional guidelines. Nilotinib monotherapy was administered at a dosage of 400 mg twice daily (800 mg/day).
The primary efficacy end point was the rate of overall hematologic response (HR), which included complete response (CR), CR with incomplete platelet recovery (CRp), partial response, hematologic improvement (HI), and stable disease. HI was defined as X50% reduction in bone marrow blasts and/or a complete clearance of peripheral blood blasts. Patients who failed to achieve at least HI, but showed no evidence of progression, were considered to have stable disease. As a measure of sensitivity, HR was also calculated on the basis of peripheral blood samples. The criteria required for calculated complete HR (CHR) were 0% blasts, a neutrophil count X1.5 Â 10 9 /l, a platelet count X100 Â 10 9 /l and basophils o5%. Marrow response (MR)/no evidence of leukemia (NEL) was defined as 0% blasts, a neutrophil count X1.0 Â 10 9 /l, a platelet count X20 Â 10 9 /l (without platelet transfusion or without evidence of bleeding), and basophils o5%. A Simon two-stage minimax design was used to assess efficacy. On the basis of this design, a sample size of 40 patients provided 90% power, with a one-sided level of significance of 10%, to test the null hypothesis H 0 : Pp0.10, where P is the HR rate assuming that the true response rate is PX0.25. Efficacy analyses were performed on a subset of the full-analysis set (FAS) that excluded any patients with MRD at baseline (non-MRD FAS). The safety set consisted of all patients who received at least one dose of study drug.
Key patient demographics are reported in Table 1 . The time since first diagnosis of Ph þ ALL varied: o1 year before study entry in 14 (34%) patients, between 1 and 2 years before study entry in 18 (44%) patients and between 2 and 5 years before study entry in 9 (22%) patients. At study entry, 21 (51%) patients were in first relapse and 15 (37%) patients were in second relapse. All patients had failed prior imatinib therapy, and other common prior antileukemia therapies included methotrexate (73%), cytarabine (68%) and cyclophosphamide (54%). Of the 18 (44%) patients for whom data on baseline BCR-ABL mutational status were available, 8 (44%) had X1 mutation (3 had the T315I mutation) and 10 (56%) had no mutation. One patient had MRD with evolving relapse and was excluded from the non-MRD FAS.
The median duration of nilotinib was 53.0 days (range, 1-1177 days). The majority (68%) of patients had a treatment duration of o3 months. At the time of data cutoff, two (5%) patients remained Accepted article preview online 9 November 2012; advance online publication, 4 December 2012 on nilotinib treatment. The remaining 39 (95%) patients discontinued treatment because of disease progression (n ¼ 26; 63%), adverse events (AE) (n ¼ 7; 17%), death (n ¼ 2; 5%), abnormal laboratory values (n ¼ 2; 5%) or withdrawal of consent (n ¼ 1; 2%).
The criterion for the first stage of the Simon 2-stage design was met, with X3 patients achieving HR among 27 patients initially enrolled. The study proceeded to enroll an additional 13 patients with no MRD at baseline, for a total of 40 patients in the non-MRD FAS. In this subset, eight patients (20%; 95% confidence interval (CI), 9.1-35.6%) had an HR and the study success criterion (X7 responders among 40 patients) was achieved (the lower 90% one-sided CI limit of 12.0% exceeded the target of 10%). Hematologic improvement was attained by five patients (12%), and nine (22%) patients had stable disease. In the sensitivity analysis, the calculated HR rate was 47% (95% CI, 31.5-63.9%); 18 (45%) patients had a CHR and 1 (2%) had a MR/ NEL. Seven patients with CHR had that level of response at baseline; five patients were not assessable for HR at baseline.
In the non-MRD FAS, 17 (42%) patients had evidence of Ph chromosome positivity at baseline on the basis of bone marrow cytogenetics (14 patients had X20 metaphases examined, and 3 patients had o20 metaphases examined at baseline). Three patients had 0% Ph þ metaphases (with X20 metaphases examined at baseline). These three patients maintained 0% Ph þ metaphases on treatment and were considered to have a complete cytogenetic response (CCyR). Six patients had fluorescence in situ hybridization (FISH) assessment at baseline. The remaining 14 patients had neither bone marrow cytogenetics nor FISH assessment of Ph at baseline. A major cytogenetic response was achieved in 20 patients (50%; 95% CI, 33.8-66.2%), and 32% of patients achieved CCyR. The patient with MRD at baseline demonstrated a CCyR throughout the study. The median overall survival in the non-MRD FAS was 5.2 months (95% CI, 3.2-8.3 months), and the estimated 12-month survival rate was 27% (95% CI, 12.8-41.2%) (Figure 1 ).
Nilotinib-related AE were reported in 83% of patients. The most frequent non-hematologic AE included nausea (29%), diarrhea (19%), headache (17%) and vomiting (15%). Grade 3/4 nonhematologic nilotinib-related AE each occurred in p5% of patients; nausea (5%) and bone pain (5%) were the most common. The most frequent newly occurring or worsening grade 3/4 hematologic AE were thrombocytopenia (63%), neutropenia (43%) and anemia (26%). Hypophosphatemia (22%), hyperbilirubinemia (15%), hyponatremia (15%) and decreased albumin (10%) were the most frequent grade 3/4 biochemical abnormalities. Median nilotinib dose intensity was 800.0 mg/day (range, 474-1007 mg/day). Dose reductions and interruptions because of AE occurred in 12% and 29% of patients, respectively, and in 29% of patients and 37% of patients overall. Median duration of dose interruption was 6 days (range, 1-42 days). AEs led to study discontinuation in eight (19%) patients, in three patients because of myelosuppression and in two because of hyperbilirubinemia. Eleven patients died during the treatment or within 28 days following treatment discontinuation-no death was suspected to be related to nilotinib.
Here we report that nilotinib, which is effective against most imatinib-resistant BCR-ABL mutant clones, may be a viable option in some patients with heavily pretreated Ph þ ALL patients. Nilotinib was generally well tolerated, with a median dose intensity equivalent to the actual planned dose. The overall AE profile was similar to that seen in studies of nilotinib in patients with Ph þ CML and as expected for this patient population. 2, 5 The optimal timing of nilotinib in the ALL treatment algorithm remains unknown. In several case studies, nilotinib has been associated with favorable responses before and after alloSCT in patients with Ph þ ALL. 7, 8 Nilotinib may be useful in combination with chemotherapy in the frontline treatment of patients with Ph þ ALL. In a small pilot study of four patients with Ph þ ALL, all four patients treated with nilotinib and dose-intensive chemotherapy achieved CRs. 9 Larger studies are underway. [10] [11] [12] The results we observed with nilotinib are comparable with those observed with dasatinib in patients with imatinib-resistant or -intolerant Ph þ ALL. 5 Our study data support future evaluations of nilotinib in both refractory patients and patients with newly diagnosed Ph þ ALL, particularly within combination therapies targeting pathways recently reported to be of significance in ALL. 13, 14 CONFLICT OF INTEREST OGO, RAL, HMK, PDLeC, MB, AH, DWK and FJG acted as a consultant for, and received research funding from Novartis, XF and SN are employees of Novartis Pharmaceuticals. Letters to the Editor
